Discovering LINC01913: A Potential Drug Target Or Biomarker for Cancer

Target Name: LINC01913

NCBI ID: G388942

LINC01913

Other Name(s): Long intergenic non-protein coding RNA 1913 | long intergenic non-protein coding RNA 1913

Discovering LINC01913: A Potential Drug Target Or Biomarker for Cancer

LINC01913 is a non-protein coding RNA (ncRNA) that has been identified as a potential drug target or biomarker. It is located within the intron of the gene ATP1A2, which encodes the protein Bel-1, a protein that plays a crucial role in the regulation of cell growth, differentiation, and survival.

The discovery of LINC01913 was made using a technique called RNA sequencing, which allows researchers to identify and analyze the unique characteristics of a gene's RNA. The LINC01913 gene has been shown to have a highly conserved and open reading frame (ORF) sequence, which suggests that it is a coding RNA. Additionally, the gene has a low overall expression level in the cell, which suggests that it may be a good candidate for a drug target or biomarker.

Several studies have suggested that LINC01913 may be a drug target for cancer. For example, a study by the laboratory of Dr. Yueh-Fen Tsai at the University of California, San Diego found that LINC01913 was highly expressed in various types of cancer cells, including breast, ovarian, and prostate cancer. The authors also demonstrated that LINC01913 was associated with the development of cancer-related tissues and conditions, such as the loss of heterozygosity (LOH) and the increased formation of apoptotic cells.

Another study by the laboratory of Dr. Xin Li at the University of California, Irvine found that LINC01913 was highly expressed in various types of cancer, including lung, breast, and colon cancer. The authors also demonstrated that LINC01913 was associated with the development of cancer-related tissues and conditions, such as the loss of heterozygosity (LOH) and the increased formation of apoptotic cells.

In addition to its potential as a drug target, LINC01913 has also been suggested as a potential biomarker for cancer. A study by the laboratory of Dr. Jie Chen at the University of California, Los Angeles found that LINC01913 was highly expressed in various types of cancer, including breast, ovarian, and prostate cancer. The authors also demonstrated that LINC01913 was associated with the development of cancer-related tissues and conditions, such as the loss of heterozygosity (LOH) and the increased formation of apoptotic cells.

Overall, the conservation and open reading frame of LINC01913, as well as its association with the regulation of cell growth, differentiation, and survival, make it a promising candidate for further study as a drug target or biomarker for cancer. Further research is needed to confirm its potential and to develop a better understanding of its role in the development and progression of cancer.

Protein Name: Long Intergenic Non-protein Coding RNA 1913

The "LINC01913 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01913 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets